New hope for rare blood cancer: platform trial tests multiple drugs at once
NCT ID NCT07018752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drugs improve outcomes. About 49 adults will take part, with the goal of gathering early data to design larger future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- roginolisib, golcadomide, and azacitidine (oral drugs)
- What this could lead to
- If successful, this trial could identify new drug combinations that improve outcomes for people with hard-to-treat peripheral T-cell lymphoma.
- What could go wrong
- This is an early-phase trial with only 49 participants, so results may not apply to all patients. The drugs may cause side effects or fail to work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH de la Côte Basque - Service Hématologie
RECRUITINGSaint-Jean-de-Luz, 64500, France
-
CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie
NOT_YET_RECRUITINGLe Mans, 72000, France
-
CHRU Nancy - Hôpital Brabois - Service Hématologie
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, 54500, France
-
CHU Dijon Bourgogne - Service Hématologie Clinique
RECRUITINGDijon, 21000, France
-
CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique
NOT_YET_RECRUITINGClermont-Ferrand, 63100, France
-
CHU Lyon-Sud - Hématologie Clinique
RECRUITINGPierre-Bénite, 69310, France
-
CHU Pontchaillou - Hématologie Clinique
NOT_YET_RECRUITINGRennes, 35000, France
-
CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire
NOT_YET_RECRUITINGPessac, 33600, France
-
CHU de Grenoble - Service Hématologie
NOT_YET_RECRUITINGLa Tronche, 38700, France
-
CHU de Lille - Hôpital Claude Huriez - Service des Maladies du Sang
RECRUITINGLille, 59000, France
-
CHU de Montpellier - Département d'Hématologie Clinique
RECRUITINGMontpellier, 34080, France
-
CHU de Nantes - Service Hématologie
RECRUITINGNantes, 44000, France
-
CHU de Poitiers - Hôpital de la Milétrie - Service d'Oncologie Hématologique et Thérapie Cellulaire
RECRUITINGPoitiers, 86000, France
-
Centre Henri Becquerel - Service Hématologie
RECRUITINGRouen, 76000, France
-
Hôpital Henri Mondor - Unité Hémopathies Lymphoïdes
RECRUITINGCréteil, 94000, France
-
Hôpital Necker - Service Hématologie Adultes
RECRUITINGParis, 75015, France
-
Institut Paoli Calmettes - Service Hématologie
NOT_YET_RECRUITINGMarseille, 13009, France
-
Institut d'Hématologie de Basse Normandie - Service Hématologie (CHU Hôpital Côte de Nacre)
RECRUITINGCaen, 14000, France
-
Institut de Cancérologie Strasbourg Europe - Service Hématologie
RECRUITINGStrasbourg, 67200, France
-
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie
RECRUITINGSaint-Etienne, 42000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Immunotherapy combo may outperform chemo in rare lymphoma
- New drug cocktail shows promise for tough lymphomas
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer